E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse |
|
E.1.1.1 | Medical condition in easily understood language |
Post-menopausal women with hormone-sensitive breast cancer at very low risk of metastatic recurrence |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006187 |
E.1.2 | Term | Breast cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10083237 |
E.1.2 | Term | Luminal A breast cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To prospectively demonstrate that an adjuvant aromatase inhibitor therapy duration limited to 2 years is associated with high distant metastasis-free survival at 5 years in a selected population with invasive breast cancer at low risk of metastatic recurrence |
|
E.2.2 | Secondary objectives of the trial |
•Evaluate Invasive Disease-Free Survival (iDFS) •Evaluate Invasive breast cancer-free survival (iBCFS) •Evaluate breast cancer specific survival (BCSS) •Evaluate overall survival (OS) •Assess quality of life (QoL) at baseline and every year until 5 years after the start of the study in term of general QoL, fatigue, psychological, and cognitive functions •Compare the survival and QoL endpoints with the breast cancer patients in the CANTO cohort who took 5 years of hormonal treatment •Evaluate the safety of the treatment in the study population |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Postmenopausal women: Postmenopausal status is defined by any of the following: - Prior bilateral oophorectomy - Age ≥60 years - Age >50 and <60 years and amenorrheic for at least 12 months, and follicle-stimulating hormone (FSH) and estradiol in the postmenopausal range 2.Eastern Cooperative Oncology Group (ECOG) performance status 0-1 3.Women with histologically proven invasive unilateral breast cancer Note: In case of a multifocal invasive tumor, all lesions (maximum 3 infiltrating lesions allowed) must be of identical phenotype and low biological risk 4.M0: Not clinically nor radiologically detectable metastases at time of inclusion 5.Primary tumor completely resected and adequate axillary surgery performed, according to current standards 6.IHC expression of the estrogen receptor and/or progesterone receptor ≥50% 7.HER2 negative according to ASCO criteria in immunohistochemistry and/or genomic analysis (HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH non-amplified]) 8.No indication of adjuvant chemotherapy 9.Patient considered has having a luminal A ultralow risk of metastatic recurrence (i.e. less than 5% risk of metastatic relapse at 10 years) according to MammaPrint® and Blueprint® tests. Note 1: MammaPrint test is indicated for patients with pT1c-2, pN0/pN1mic and grade 2, with no indication of chemotherapy. Note 2: Up to 80 patients aged ≥65 years and pT1 (tumor ≤20 mm) and pN0 and grade 1 and Ki67 ≤10% will be recruited Note 3: To be eligible, MammaPrint index score should be > +0.355 10.Patients eligible to receive or have recently started (with a maximum of 4 months of adjuvant hormone therapy prior to enrollment) an adjuvant hormone therapy (letrozole, anastrozole, or exemestane) 11.Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures 12.Patients must be affiliated to a Social Security System (or equivalent) 13.Patient must have signed a written informed consent form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient’s consent
|
|
E.4 | Principal exclusion criteria |
1.Patients who received a neo-adjuvant hormone therapy (only 4 months prior to enrollment will be allowed), a neo-adjuvant or adjuvant chemotherapy or preoperative medical treatment 2.Any local or regional recurrence or metastatic disease 3.Non-invasive carcinoma 4.Bilateral breast cancer (except in case of contralateral DCIS), or history of other invasive ipsi- or contralateral breast cancer 5.Patients with a history of another malignancy except for properly treated cervical carcinoma in situ and non-melanoma cancer of the skin 6.Women with high-risk breast cancer predisposing deleterious germline mutations 7.Contra-indications to the administration of anti-aromatase inhibitors 8.Patients enrolled in another therapeutic study within 30 days of inclusion 9.Patients with any other disease or illness, which requires hospitalization or is incompatible with the trial treatment 10.Patients unwilling or unable to comply with trial obligations for geographic, social, physical or psychological reasons, or who are unable to understand the purpose and procedures of the trial 11.Persons deprived of their liberty or under protective custody or guardianship |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Distant metastasis–free survival (DMFS) defined as the time from date of registration to date of first event of distant recurrence, death, or second primary non-breast invasive cancer |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•Invasive disease free survival (iDFS): defined as duration of time from date of registration until first appearance of invasive local, regional, or distant recurrence (including invasive ipsilateral breast cancer recurrence), invasive contralateral breast cancer, second primary non breast invasive cancer (excluding non-melanoma skin cancer), or death from any cause. Invasive breast cancer–free survival (iBCFS) is similar to iDFS but excluding second primary non breast invasive cancers. •Breast cancer specific survival (BCSS): defined as the time from registration to death from breast cancer; or censored at date the person was last known alive. •Overall survival (OS): defined as the time from date of registration to date of death due to any cause •Quality of life will be assessed at baseline and every year up to five years post study entry using the following questionnaires: oEORTC QLQC30 , an integrated system for the evaluation of health-related Qol of cancer patients, employed in over 2,000 cancer clinical trials and extensively validated, which includes functional scales for physical, role, cognitive, emotional, and social functioning, symptom scales for fatigue, pain, and nausea/vomiting, and single items for dyspnea, appetite loss, insomnia, constipation and diarrhea. oThe breast cancer specific companion modules EORTC QLQ-BR23/QLQ-BR45 used in conjunction with the EORTC QLQ-C30, are valid and reliable in breast cancer specific Qol assessment, including body image and systemic therapy side effects. The QLQ-BR-23 was updated and 22 new questions were added to provide a more accurate and comprehensive assessment of the impact of new and scalable treatments on patients’QoL. o The fatigue subscale EORTC QLQ-F12, including emotional, cognitive and physical fatigue subscales. o Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS) (14-item scale (7 items for depression and 7 for anxiety) that has been validated in many languages and settings including general practice and community settings. o Cognitive complaints will be assessed by a validated self-reported Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3. o Impact of Cancer (including fear of recidivism) will be assessed by the Questionnaire version 2 IOCv2. •For all the above mentioned parameters, LESS patients will be compared to patients treated with 5 years of hormonotherapy for the same cancer histotype in the CANTO study •Safety: Adverse Events will be graded according to NCI-CTCAE v5.0
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 50 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 12 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |